Antipodocalyxin Antibody chPcMab-47 Exerts Antitumor Activity in Mouse Xenograft Models of Colorectal Adenocarcinomas

2017 ◽  
Vol 36 (4) ◽  
pp. 157-162 ◽  
Author(s):  
Mika K. Kaneko ◽  
Akiko Kunita ◽  
Shinji Yamada ◽  
Takuro Nakamura ◽  
Miyuki Yanaka ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Mouse Xenograft ◽  
Xenograft Models ◽  
Colorectal Adenocarcinomas

scholarly journals OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models

2006 ◽  
Vol 66 (2) ◽  
pp. 1015-1024 ◽  
Author(s):  
Andrew J. Garton ◽  
Andrew P.A. Crew ◽  
Maryland Franklin ◽  
Andrew R. Cooke ◽  
Graham M. Wynne ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Tyrosine Kinases ◽  
Receptor Tyrosine Kinases ◽  
Selective Inhibitor ◽  
Mouse Xenograft ◽  
Kinase Insert Domain Receptor ◽  
Xenograft Models

scholarly journals An anti‑TROP2 monoclonal antibody TrMab‑6 exerts antitumor activity in breast cancer mouse xenograft models

2021 ◽  
Vol 46 (1) ◽  
Author(s):  
Tomohiro Tanaka ◽  
Tomokazu Ohishi ◽  
Teizo Asano ◽  
Junko Takei ◽  
Ren Nanamiya ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Monoclonal Antibody ◽  
Antitumor Activity ◽  
Mouse Xenograft ◽  
Xenograft Models

scholarly journals Antitumor activity of Endostar combined with radiation against human nasopharyngeal carcinoma in mouse xenograft models

2012 ◽  
Vol 4 (5) ◽  
pp. 976-980 ◽  
Author(s):  
JUYING ZHOU ◽  
LILI WANG ◽  
XIAOTING XU ◽  
YU TU ◽  
SONGBING QIN ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Antitumor Activity ◽  
Mouse Xenograft ◽  
Human Nasopharyngeal Carcinoma ◽  
Xenograft Models

scholarly journals The mouse–canine chimeric anti-dog podoplanin antibody P38B exerts antitumor activity in mouse xenograft models

2019 ◽  
Vol 17 ◽  
pp. 23-26 ◽  
Author(s):  
Yukinari Kato ◽  
Tomokazu Ohishi ◽  
Manabu Kawada ◽  
Naoya Maekawa ◽  
Satoru Konnai ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Mouse Xenograft ◽  
Xenograft Models

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

Blood ◽  
2003 ◽  
Vol 102 (4) ◽  
pp. 1458-1465 ◽  
Author(s):  
Joseph A. Francisco ◽  
Charles G. Cerveny ◽  
Damon L. Meyer ◽  
Bruce J. Mixan ◽  
Kerry Klussman ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Scid Mouse ◽  
Severe Combined Immunodeficiency ◽  
Growth Arrest ◽  
Large Cell ◽  
Hodgkin Disease ◽  
Antibody Drug Conjugate ◽  
Mouse Xenograft ◽  
Xenograft Models

Abstract The chimeric monoclonal antibody cAC10, directed against CD30, induces growth arrest of CD30+ cell lines in vitro and has pronounced antitumor activity in severe combined immunodeficiency (SCID) mouse xenograft models of Hodgkin disease. We have significantly enhanced these activities by conjugating to cAC10 the cytotoxic agent monomethyl auristatin E (MMAE) to create the antibody-drug conjugate cAC10-vcMMAE. MMAE, a derivative of the cytotoxic tubulin modifier auristatin E, was covalently coupled to cAC10 through a valine-citrulline peptide linker. The drug was stably attached to the antibody, showing only a 2% release of MMAE following 10-day incubation in human plasma, but it was readily cleaved by lysosomal proteases after receptor-mediated internalization. Release of MMAE into the cytosol induced G2/M-phase growth arrest and cell death through the induction of apoptosis. In vitro, cAC10-vcMMAE was highly potent and selective against CD30+ tumor lines (IC50 less than 10 ng/mL) but was more than 300-fold less active on antigen-negative cells. In SCID mouse xenograft models of anaplastic large cell lymphoma or Hodgkin disease, cAC10-vcMMAE was efficacious at doses as low as 1 mg/kg. Mice treated at 30 mg/kg cAC10-vcMMAE showed no signs of toxicity. These data indicate that cAC10-vcMMAE may be a highly effective and selective therapy for the treatment of CD30+ neoplasias.

Sign in / Sign up

Export Citation Format

Share Document